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Summary
Objectives: The transglutaminase (TGase) family includes seven different enzymes that catalyse a protein cross-linking reaction resulting in
structural and functional alterations in substrate proteins. TGase activity is easily measureable in mature articular cartilage where it may
contribute to CPPD deposition disease through its actions on growth factors, crystal components or extracellular matrix proteins. In contrast,
low levels of TGase activity are found in chondrocytes from young animals. We previously demonstrated type II TGase protein in articular
chondrocytes. Earlier work also suggested the presence of another form of TGase in chondrocytes. We sought to determine if articular
chondrocytes contain the TGase, Factor XIIIA (FXIIIA).
Methods: Western blots with FXIIIA antibody were used to detect FXIIIA in young and old porcine articular chondrocytes and articular
cartilage vesicles (ACVs). The presence of FXIIIA mRNA was confirmed by RT-PCR.
Results: Old chondrocyte conditioned medium, cytosol, and membrane fractions contained FXIIIA protein on Western blots, while less FXIIIA
was detectable in cell fractions or media from young chondrocytes. ACVs also contained FXIIIA. FXIIIA mRNA was demonstrated by PCR
in old and young chondrocytes.
Conclusions: FXIIIA is present in articular chondrocytes. FXIIIA levels correlate with TGase activity in chondrocytes. The presence of two
forms of TGase in articular chondrocytes suggest an important function for this enzyme family in articular cartilage. © 2001 OsteoArthritis
Research Society International
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The transglutaminases (TGases, E.C. 2.3.2.13) catalyse a
calcium dependent cross-linking of proteins resulting in
modifications that alter the structure and functions of its
substrates1. In many types of connective tissues, including
bone and cartilage, TGases participate in processes such
as matrix mineralization and binding and activation of
growth factors. They regulate concentrations and locations
of TGase substrates such as fibronectin, osteonectin and
microfibrillar proteins2,3. To date, at least seven enzymes
with TGase activity have been identified and character-
ized1. Type II TGase and Factor XIIIA( FXIIIA) are the most
widely distributed members of the TGase family. Type II (or
tissue) TGase is a 77 kDa protein found in most cell types1.
Factor XIIIA is an 85 kD protein which was initially
described in its circulating form as part of a calcium-
dependent, thrombin-activatable tetramer involved in the
clotting cascade4. In its cellular form, FXIIIA can be acti-
vated without exposure to thrombin and is not found in
association with B chains. Available enzyme activity assays
are not able to distinguish between different forms of
TGase5.
We became interested in TGase in articular cartilage
because of its possible participation in the processes of578pathologic mineralization that occur in aging cartilage and
result in calcium pyrophosphate (CPPD) deposition dis-
ease. We previously demonstrated a dramatic seven-fold
increase in TGase activity in aging articular chondrocytes
compared to chondrocytes from young animals. TGase
levels in cytosol fractions were 13.4±4 U/mg protein and
6.0±0.6 U/mg protein in membrane fractions of old
chondrocytes, while levels were 1.8±0.7 U/mg protein in
the cytosol and were undectable in the membrane fractions
of young chondrocytes6. The comparison of young
chondrocytes with low TGase activities with old chondro-
cytes with high TGase activities has proven to be a useful
model to study the role of this enzyme family in articular
cartilage.
We recently showed that TGase participates in several
key processes involved in CPPD crystal formation in
articular cartilage. TGase aids in the activation of the
CPPD crystal-promoting growth factor, latent transforming
growth factor  (TGF), in aging chondrocytes7. Inhibition
of TGase activity suppresses production of the CPPD
precursor, pyrophosphate (PPi)6.
Type II TGase protein is present in both young and old
articular chondrocytes6. In addition to differences in total
TGase enzyme activity, the cellular distribution of TGase
activity differs in old and young porcine articular chondro-
cytes. Higher levels of Type II TGase protein are found in
old chondrocytes compared to young ones. Although cyto-
plasmic TGase activity in chondrocytes correlates with the
presence of Type II TGase protein by Western blot, little
type II protein is detectable in the membrane fraction of
aging chondrocytes, despite easily measurable enzyme
activity in the membrane fraction6. These findings suggest
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CHONDROCYTE CULTURES
Porcine articular cartilage from knees were obtained
from old (3–5 years) and young (2 weeks) animals.
Chondrocytes were enzymatically released from matrix
using 0.5 mg/ml hyaluronidase for 10 min, 0.3 mg/ml
trypsin and 0.75 mg/ml collagenase for 10 min, followed by
0.5 mg/ml collagenase in Dulbecco’s Modified Eagle
Medium (DMEM, Mediatech Inc., Herndon, VA) with 10%
Fetal Bovine Serum (FBS, Mediatech ) overnight with
stirring at 37°C. Cells were plated at a density of 4.5×105
cells/cm2 in DMEM with 10% FBS and 1% PenStrep
Fungizone (PSF, Mediatech) for 24 h. Cells plated at this
density retain the differentiated chondrocyte phenotype in
short term cultures11. All experiments were done in serum-
free DMEM within 48 h of plating.ARTICULAR CARTILAGE VESICLES (ACVS)
Articular cartilage vesicles were prepared from old and
young cartilage digests as previously described10. Vesicles
were further divided into light and heavy vesicles fractions.
These fractions differ in their protein and enzyme content,
but both are capable of generating CPPD crystals in vitro10.WESTERN BLOTTING
Cells were cultured for 72 h in serum-free DMEM with
1 mg/ml bovine serum albumin prior to Western blotting.
The medium was removed from the plates and the cells
were lysed. For some experiments, cell lysates were further
processed by centrifugation at 6000×g for 5 min to remove
debris and then at 48,000×g for 30 min at 4°C to separate
cytosol from membrane fractions. This results in a fraction
enriched in cytosolic proteins and one enriched in
membrane proteins, although certainly some cross-
contamination occurs. The cell fractions, whole cell lysates,
or samples of conditioned media were run in Western blots
using 450 nanograms of protein in each lane6. Anticoagu-
lation Factor XIII, A-Subunit (Calbiochem, La Jolla, CA)
was used at a 1:1000 dilution. This antibody is specific for
FXIIIA and does not cross-react with FXIIIB or Factor XII.There is a 40% homology between type II TGase and
FXIIIA. However, we showed no cross-reactivity when
purified type II TGase was run in a Western blot with FXIIIA
antibody. (Data not shown.) Laser densitometry was used
to quantitate the density of the bands in some experiments.REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
(RT-PCR)
Total RNA from chondrocytes was isolated by the
acidified guanidinium isothiocyanate method, using TRIzol
(Life Technologies, Grand Island, NY). Total RNA was
reverse transcribed in the presence of 50 pM oligo
(dT12–18) primer (Life Technologies), 10 mM dithiothreitol,
0.5 mM of each dNTPs (Life Technologies), first strand
buffer 5×, and 60 units of Moloney murine leukemia virus
RNase H− reverse transcriptase (SUPERSCRIPT II, Life
technologies). Amplification of generated cDNA was per-
formed in an GeneAmp PCR System 2400 thermocycler
(Perkin-Elmer Biosystems, Foster City, CA) using a
PLATINUM PCR SUPERMIX (Life technologies). The
gene specific primer pair for FXIIIA was sense 5′-TCAATG
ACATCAAGACCAGAAG-3′, and antisense 5′-GACACCA
GCAAAAACCCAG-3′12. Transcripts were analysed in
1.6% agarose/TAE gel electrophoresis and visualized by
SYBR GREEN-I (Sigma, St. Louis, MO) using the Alpha
Imager 2000 system (AlphaInotech Co., San Leandro,
CA). Each PCR product was isolated from the agarose gel
and the sequence confirmed by dideoxy chain-termination
sequencing13.STATISTICS
All experiments were repeated at least 3 times to confirm
the results.Results
FXIIIA is present in articular chondrocytes and increases
with age. As shown in the representative Western blot in
Fig. 1, FXIIIA is present in the media, membrane and
cytosolic fractions of cultured chondrocytes. Quantities of
FXIIIA protein are greater in old chondrocyte cell fractions
and conditioned media than in young chondrocyte cell
fractions and conditioned media matched for protein con-
tent. In old chondrocytes, the immunoreactive band
appears as a double band in the cytosolic fraction and is a
single band in the membrane fractions and conditioned
media.
Old and young chondrocytes contain mRNA for FXIIIA.
As shown in Fig. 2, both old and young chondrocytes
contain mRNA for FXIIIA as determined by RT-PCR and
illustrated by the presence of a fragment with molecular
weight corresponding to the expected weight of the FXIIIA
fragments. This confirms the presence of mRNA for FXIIIA
in articular chondrocytes. This method is not sensitive to
small differences in levels of mRNA and cannot be used
to compare FXIIIA mRNA levels in old and young
chondrocytes.
FXIIIA is present in ACVs. The Western blot in Fig. 3
demonstrates FXIIIA in ACVs from old and young pigs.
FXIIIA levels are roughly equivalent in old and young ACVs
and are present in both heavy and light vesicle fractions.
The distribution of FXIIIA differs in heavy and light vesicle
fractions from old and young animals.the existence of at least two forms of TGase in aging
articular chondrocytes.
The TGase enzyme, FXIIIA, was recently identified in
hypertrophic growth plate chondrocytes8. Hypertrophic
growth plate chondrocytes have much in common with
aging articular chondrocytes9. Both of these cell types are
associated with matrix mineralization and both elaborate
small membrane bound particles known as matrix
vesicles10. The articular cartilage counterpart of the matrix
vesicle, the articular cartilage vesicle (ACV), contains type
II TGase, and may serve as a mode of extracellular
transport for TGase and other proteins lacking signal
sequences common on proteins destined for export6.
The purpose of the current work was to determine
whether old and young articular chondrocytes and ACVs
contain FXIIIA. We report here that FXIIIA protein and
mRNA are present in articular chondrocytes and ACVs.
Furthermore, in conjunction with total TGase activity levels
and type II TGase protein levels, FXIIIA protein levels are
increased in chondrocytes from old animals compared to
levels in chondrocytes from young animals.
580 A. K. Rosenthal et al.: Factor XIIIA in cartilageFig. 1. Western blot with FXIIIA antibody of old and young
chondrocyte cell fractions and conditioned media. Chondrocytes
were cultured in serum-free media for 72 h. Cells were lysed, and
cytosol and membrane fractions were separated by differential
centrifugation. Human plasma was used as a positive control. After
SDS-PAGE, blots were exposed to FXIIIA antibody and Western
blotting. (A) Old cytosol, (B) Young cytosol, (C) Old membrane,
(D) Young membrane, (E) Old media, (F) Young media, (G) Human
plasma.Fig. 2. RT-PCR using FXIIIA primer pairs. Using total RNA from old
and young chondrocytes, cDNA for FXIIIA was detected by
RT-PCR using a primer pair for FXIIIA with an expected size of
313 bp and a control for GAPDH of 496 bp. (A) MW markers, (B)
Old chondrocytes, FXIIIA , (C) Young chondrocytes, FXIIIA, (D)
MW markers, (E) Old chondrocytes, GAPDH (F) Young chondro-
cytes, GAPDH.Fig. 3. Western blot with FXIIIA antibody of ACVs. Old and young
ACVs were prepared as described and used in Western blots with
FXIIIA antibody. The bar graph represents relative densities of the
bands on the Western blot. (A) Old ACV heavy vesicle fraction;
(B) Old ACV light vesicle fraction, (C) Young ACV heavy vesicle
fraction, (D) Young ACV light vesicle fraction.Discussion
We show here that the TGase, FXIIIA, is present in
articular chondrocytes and FXIIIA protein levels are higher
in old chondrocytes with high total TGase activities than in
young chondocytes with low total TGase activies . Although
FXIIIA is present in growth plate chondrocytes8, and a
thrombin-activatable TGase was identified in young rabbit
articular chondrocytes14, ours is the first work to clearly
demonstrate FXIIIA in articular chondrocytes. RT-PCR data
confirm the presence of FXIIIA mRNA in articular chondro-
cytes. High levels of FXIIIA in combination with increased
type II TGase levels in old chondrocytes may account for
the marked increase in measurable TGase activity in old
compared to young chondrocytes.While type II TGase is principally present in the cytosolic
fraction of lysed cells6, FXIIIA protein appears to be evenly
distributed between membrane and cytosolic fractions of
old chondrocytes. FXIIIA is also secreted into culture
medium. As many of the key functions of TGase occur on or
outside the cell, FXIIIA may play an even more important
role than type II TGase in mediating the physiologic or
pathologic functions of TGase in articular cartilage. The
significance of the double immunoreactive bands in the
cytosol fraction and the single bands in the membrane,
media fractions, and ACVs are unknown. Proteolytic modi-
fications or differences in glycosylation may account for the
double band in the cytosolic fractions. FXIIIA can be
cleaved to FXIIIa, the active form of the molecule, by
thrombin or through other means. The antibody recognizes
both FXIIIA and FXIIIa, but whether the lower molecular
weight band represents an activated form of the molecule
remains to be determined.
Factor XIIIA is present in ACVs from both old and young
chondrocytes, and these vesicles probably aid in the export
of TGases to the extracellular space. ACVs participate in
CPPD crystal formation, but may also act as repositories of
matrix-modifying enzymes and cytokines distant from the
cell15. The distribution of FXIIIA protein differs in heavy and
light vesicle fractions from old and young cartilage. The
signficance of this finding is unknown, although levels of
other enzymes such as nucleoside triphosphate pyrophos-
phohydrolase are also different in light and heavy ves-
icles10. These vesicles fractions are not well characterized
in young chondrocytes in regard to mineralizing ability
and further work is necessary in order to understand the
significance of these findings.
The function of FXIIIA in cartilage is unknown. The
circulating form of FXIIIA is a zymogen, and requires high
calcium levels and thrombin for activation. In contrast, the
cellular form of FXIIIA can be activated non-enzymatically
and at physiologic intracellular [Ca]2+16. Potential sub-
strates for cellular FXIIIA in cartilage include fibronectin,
osteopontin, and thrombospondin4. We previously showed
that TGase inhibitors suppress PPi production, and reduce
the amount of latent TGF activated by chondrocytes6,7,
thus implicating these enzymes in CPPD crystal formation.
These studies are not without limitations. Nurminskaya
suggested that increases in extracellular FXIIIA activity
resulted from leakage of cell contents from dying cells8.
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ous FXIIIA may bind to cells, and small quantities are
present in serum, we were careful to use serum-free
medium with a prolonged wash-out period in these exper-
iments. We have used a model of old and young chondro-
cytes that may reflect developmental differences rather
than differences of adult aging. This model has proven a
useful comparison of chondrocytes with high to those with
low TGase activity levels. Further studies to examine the
role of adult aging on TGase activity and protein levels are
under way in our laboratory.
In conclusion, we show here that like type II TGase,
FXIIIA is present in articular chondrocytes and in ACVs.
FXIIIA protein levels are increased in aging chondrocytes
with high TGase activity compared to young chondrocytes
with low TGase activity levels. The presence of two
enzymes with TGase activity in aging chondrocytes sug-
gests an important role for this family of enzymes in
cartilage. The participation of TGase in such processes
as matrix protein modification, PPi production, and
latent TGF activation supports the hypothesis that
the TGases may participate in CPPD crystal deposition
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